Analysts expect Tempest Therapeutics to report zero revenue and a consensus EPS loss of $0.32 for Q3 2026, while the $0.74 stock price continues to trade at a deep discount to the $7.33 average analyst target. The primary focus for investors is the clinical execution of TPST-1120, specifically the operational progress of its pivotal Phase 3 trial in first-line hepatocellular carcinoma.

Management is expected to provide updates on the company's cash runway, which is critical for sustaining development through 2027 following recent capital raises. Investors are also seeking clarity on potential strategic partnerships for the PPARα antagonist program, which remains the company's most significant valuation driver.